Abstract:The activation of adaptive antitumor immune response is paramount for improving the long-term antitumor efficiency. Chemotherapy, radiotherapy, and photodynamic therapy (PDT) can induce cell apoptosis and immunogenic cell death (ICD). Subsequently, the exposure or release of damage-associated molecular patterns (DAMPs) caused by ICD can stimulate the immune system to exert an antitumor immune response, recruit the antigen-presenting cells, and activate the adaptive immune responses of T cells. As such, the application of ICD inducers in tumor therapy is of crucial role in improving the therapeutic effects and the survival rate of cancer patients. Recently, accumulating evidence has revealed that nanomaterials-based platforms for cancer treatment could not only achieve controlled drug release in response to stimulation of tumor microenvironment (TME), but also regulate TME to enhance ICD in the tumor. Hence, the construction of ICD effects-based biomedical nanomaterials has sparked tremendous attention. Benefiting from their unique size, biomedical nanomaterials are commonly applied as ICD inducers carriers to target tumor tissue and enhance selective enrichment in the tumor. By taking advantage of their easily modified surface properties and multi-selectivity of raw materials, nanomaterials can also be designed as functionalized carriers with stimulus responses to TME, thereby achieving stepwise and controlled release of ICD inducers. Meanwhile, biomedical nanomaterials are capable of codelivering different components, protecting the payload from degradation and precise controlled release. These abilities enable nanomaterials to amplify the antitumor effects of chemotherapy, radiotherapy, PDT and many other emerging therapies. Of note, a single therapy has been limited by many factors. Chemotherapy and radiotherapy can bring about irreversible damage to normal tissue cells and immune cells. The hypoxic TME limits the function of PDT. On top of that, monotherapy has been also vulnerable to tumor heterogeneity. On this ground, combination therapy has become the prior option for cancer therapy. Furthermore, the synergistic of these therapies with immune checkpoints, immunosuppressive factors, immune adjuvants, immune cells and other strategies that can enhance ICD has been extensively estimated. In this paper, we first introduced the generation of the ICD, then emphasized the multifunctional roles of nanomaterials in inducing ICD and regulating the microenvironment of tumor cells. Ulteriorly, the tremendous potential, challenges and development trends of nanomaterials in therapeutic effects of ICD have been expounded and concluded. Finally, to make better use of nanomaterials and accelerate clinical transformation in the future, it is imperative to further explore the transfer efficiency, degradation and metabolism of nanomaterials, and propose a more specific and in-depth understanding of the molecular mechanism of ICD.

Nanomedicine-mediated Immunogenic Cell Death and Its Combination with Immune Checkpoint Blockade Therapy

Combination Cancer Immunotherapy Of Nanoparticle-Based Immunogenic Cell Death Inducers And Immune Checkpoint Inhibitors

Applying Nanotechnology to Boost Cancer Immunotherapy by Promoting Immunogenic Cell Death

Nanomaterials: leading immunogenic cell death-based cancer therapies

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Biomedical Nanomaterials for the Enhancement of Immunogenic Cell Death-Based Cancer Immunotherapy

Multifunctional Nano‐Biomaterials for Cancer Therapy Via Inducing Enhanced Immunogenic Cell Death

Role of Nanoparticle-Mediated Immunogenic Cell Death in Cancer Immunotherapy

Nanomedicine-mediated Regulated Cell Death in Cancer Immunotherapy.

Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy

Promotion of ICD Via Nanotechnology.

Nanomedicine-induced Programmed Cell Death Enhances Tumor Immunotherapy

Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

Recent advance of nanosized drug delivery systems targeting immune checkpoints for combination cancer immunotherapy

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Engineering Immunogenic Cell Death with Nanosized Drug Delivery Systems Improving Cancer Immunotherapy.

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

Nanomaterials-Based Photodynamic Therapy with Combined Treatment Improves Antitumor Efficacy Through Boosting Immunogenic Cell Death

Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy

The Application of Nanoparticles-Based Ferroptosis, Pyroptosis and Autophagy in Cancer Immunotherapy